Skip to content

KADCYLA drug use surveillance

KADCYLA drug use surveillance - KADCYLA drug use surveillance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000017702
Enrollment
250
Registered
2015-05-27
Start date
2014-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with breast cancer who are scheduled to start receiving KADCYLA during this surveillance enrollment period at the first time.

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

MeasureTime frame
Safety;ADR occurence

Secondary

MeasureTime frame
Efficacy;Response rate per investigator assessment

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co., Ltd. Real World Data Science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026